Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT07239271Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of paclitaxel, pyrotinib, everolimus in HER2-positive breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
paclitaxelpyrotinibeverolimus
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07239271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239271.